Back to search

Peptide record

TPDB19865

Antibacterial Anticancer Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB19865
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
GGVKRFKKFFRKLKKSV
Physicochemical Analysis
C98H165N29O19
ANDCEQHIMPTWY
K
2053.57
12.46
8
0
6
+8
3.90
-0.788
57.06
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
0
I
1
L
6
K
0
M
3
F
0
P
1
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 1 K: 6 M: 0 F: 3 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
17
C98H165N29O19
2053.57
12.46
+8
3.90
-0.788
Evidence Records 20 records
Evidence 1 Activity

Activity

IC50
Toxicity
85.1±6.9 µM
Cytotoxic
IC50 | 85.1±6.9 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 2 Activity

Activity

IC50
Toxicity
72.2±6.9 µM
Cytotoxic
IC50 | 72.2±6.9 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 3 Activity

Activity

<10% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
<10% Hemolysis | 160 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 4 Activity

Activity

IC50
Toxicity
83.2±7.8 µM
Cytotoxic
IC50 | 83.2±7.8 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 5 Activity

Activity

IC50
Toxicity
68.7±5.7 µM
Cytotoxic
IC50 | 68.7±5.7 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 6 Activity

Activity

IC50
Toxicity
74.1±6.5 µM
Cytotoxic
IC50 | 74.1±6.5 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 7 Activity

Activity

IC50
Toxicity
67.1±4.2 µM
Cytotoxic
IC50 | 67.1±4.2 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 8 Activity

Activity

10% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
10% Hemolysis | 160 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 9 Activity

Activity

IC50
Toxicity
69.2±4.4 µM
Cytotoxic
IC50 | 69.2±4.4 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 10 Activity

Activity

IC50
Toxicity
65.9±5.4 µM
Cytotoxic
IC50 | 65.9±5.4 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 11 Activity

Activity

<10% Hemolysis
Toxicity
80 µM
Hemolytic Cytotoxic
<10% Hemolysis | 80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 12 Activity

Activity

<18% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
<18% Hemolysis | 160 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 13 Activity

Activity

IC50
Toxicity
67.6±5.4 µM
Cytotoxic
IC50 | 67.6±5.4 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 14 Activity

Activity

IC50
Toxicity
63.3±5.0 µM
Cytotoxic
IC50 | 63.3±5.0 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 15 Activity

Activity

10% Hemolysis
Toxicity
80 µM
Hemolytic Cytotoxic
10% Hemolysis | 80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. | Org Biomol Chem | 2015
Evidence 16 Activity

Activity

IC50
Toxicity
85.1
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: <20% Hemolysis =160 µM | Cytotoxicity: GES-1: IC50=85.1 ± 6.9 µM HEK293: IC50=72.2 ± 6.9 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Org Biomol Chem. 2015 Jul 28 13(28):7673-80.
Evidence 17 Activity

Activity

IC50
Toxicity
83.2
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: <20% Hemolysis =160 µM | Cytotoxicity: GES-1: IC50=83.2 ± 7.8 µM HEK293: IC50=68.7 ± 5.7 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Org Biomol Chem. 2015 Jul 28 13(28):7673-80.
Evidence 18 Activity

Activity

IC50
Toxicity
74.1
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: <20% Hemolysis =160 µM | Cytotoxicity: GES-1: IC50=74.1 ± 6.5 µM HEK293: IC50=67.1 ± 4.2 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Org Biomol Chem. 2015 Jul 28 13(28):7673-80.
Evidence 19 Activity

Activity

IC50
Toxicity
69.2
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: <20% Hemolysis =160 µM | Cytotoxicity: GES-1: IC50=69.2 ± 4.4 µM HEK293: IC50=65.9 ± 5.4 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Org Biomol Chem. 2015 Jul 28 13(28):7673-80.
Evidence 20 Activity

Activity

IC50
Toxicity
67.6
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: <20% Hemolysis =160 µM | Cytotoxicity: GES-1: IC50=67.6 ± 5.4 µM HEK293: IC50=63.3 ± 5.0 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Org Biomol Chem. 2015 Jul 28 13(28):7673-80.